TDAC · Translational Development Acquisition Corp. · Executive Compensation
$10.86
-0.04 (-0.37%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the Company's assessment of going concern considerations in accordance with ASC 205-40, "Presentation of Financial Statements-Going Concern," management has determined that the liquidity issues and mandatory liquidation and subsequent dissolution, should the Company be unable to complete a Business Combination by the end of the Completion Window, raise substantial doubt about the Company's ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after June 24, 2027. The Company's plan to deal with the uncertainty is to complete a Business Combination prior to June 24, 2027 and to receive working capital from its Sponsor. There is no assurance that the Company's plans to consummate a Business Combination or to receive working capital from the Sponsor will be successful.”View the 10-Q filed Aug 14, 2026
Market Cap
$209.69M
Shares
19.31M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher Jarratt | director | Appointed | 2024-12-27 |
| Matthew A. Kestenbaum | director | Appointed | 2024-12-27 |
| Curtis T. Keith | director | Appointed | 2024-12-27 |
| E. Premkumar Reddy | director | Appointed | 2024-12-27 |